Evidence map›Paper›PMID 40665456›Full record

Observational studyCancer imaging : the official publication of the International Cancer Imaging Society2025

The tumour sink effect on

Atefeh Zamanian, Étienne Rousseau, François-Alexandre Buteau, Frédéric Arsenault, Alexis Beaulieu, Geneviève April, Daniel Juneau, Nicolas Plouznikoff, Éric E Turcotte, Catherine Allard and 5 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04000776 (Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04000776 completednot on this map

Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies

TypeobservationalSponsorUniversité de SherbrookeRan2019 to 2023Enrolled100ConditionsMetastatic Castration-resistant Prostate CancerArmsFDG Positron emission tomography (PET) scan, PSMA Positron emission tomography (PET) scan, OCTREOTATE Positron emission tomography (PET) scan, Optional Bone or soft-tissue biopsies
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Atefeh ZamanianDepartment of Radiology and Nuclear Medicine; and Cancer Research Centre, Université Laval, Quebec City, QC, Canada.
Étienne RousseauDepartment of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
François-Alexandre ButeauDivision of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, 11 Côte du Palais, Quebec City, QC, G1R 2J6, Canada.
Frédéric ArsenaultDivision of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, 11 Côte du Palais, Quebec City, QC, G1R 2J6, Canada.
Alexis BeaulieuDivision of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, 11 Côte du Palais, Quebec City, QC, G1R 2J6, Canada.
Geneviève AprilDivision of Nuclear Medicine, Department of Medical Imaging, CHU de Québec - Université Laval, 11 Côte du Palais, Quebec City, QC, G1R 2J6, Canada.
Daniel JuneauDepartment of Radiology and Nuclear Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Nicolas PlouznikoffDepartment of Radiology and Nuclear Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Éric E TurcotteDepartment of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Catherine AllardUnité de recherche clinique et épidémiologique, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Patrick O RichardDivision of Urology, Department of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Fred SaadDivision of Urology, Department of Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Brigitte GuérinDepartment of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Frédéric PouliotOncology Axis, CHU de Québec - Université Laval Research Centre, Quebec City, QC, Canada.
Jean-Mathieu BeauregardDepartment of Radiology and Nuclear Medicine; and Cancer Research Centre, Université Laval, Quebec City, QC, Canada. jean-mathieu.beauregard@crchudequebec.ulaval.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe tumour sink effect is a phenomenon whereby the sequestration of a radiopharmaceutical in cancer lesions leads to decreased activity concentration in the blood stream and organs. The aim of this sub-analysis of the prospective 3TMPO study (NCT04000776) was to investigate the tumour sink effect on prostate-specific membrane antigen (PSMA) PET imaging in a population of patients with metastatic castration-resistant prostate cancer (mCRPC).

methodsNinety-seven participants underwent

resultsThe TLF ranged from 0.0 to 43.5%. For all healthy tissues, the %IA/cm

conclusionThe tumour sink effect was observed in a cohort of mCRPC patients scanned with

trial registrationNCT04000776, registered on 2019-06-27.

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAgedAged, 80 and overAntigens, SurfaceGallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedProspective StudiesTissue DistributionAntigens, SurfaceDipeptidesgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingRadiopharmaceuticalsPET/CTProstate cancerProstate-specific membrane antigen (PSMA)PSMA-617Radiopharmaceutical therapySink effectTotal lesion fraction (TLF)

Identifiers

PMID40665456
PMCPMC12261768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.